Liver Fibrosis Treatment Market Size, Share and Trends 2025 to 2034

Liver Fibrosis Treatment Market Size and Forecast 2025 to 2034

The global liver fibrosis treatment market size accounted for USD 18.32 billion in 2024 and is expected to exceed USD 52.26 billion by 2034, growing at a CAGR of 11.05% from 2025 to 2034. The liver fibrosis treatment market is growing due to increasing disease incidence such as NAFLD, hepatitis, and cirrhosis. These include improved drug innovation and enhanced diagnosis.  

Liver Fibrosis Treatment Market Key Takeaways

• North America dominated the liver fibrosis treatment market with the biggest market share of 38% in 2024.
• Asia Pacific is anticipated to witness the fastest CAGR of 11.12% during the forecasted years.
• By treatment type, the hepatotropic drug segment generated the highest market share in 2024.
• By condition, the hepatitis C segment contributed the largest market share in 2024.
• By end-user, the hospitals segment led the global market in 2024.

Artificial Intelligence (AI) Integration in the Liver Fibrosis Treatment Market

Integration of artificial intelligence in the liver fibrosis treatment market includes prediction of the future distribution of liver diseases, search for cheaper diagnostic tools for early liver disease detection, understanding of the mechanisms of pathogenesis of liver fibrosis, cirrhosis, and hepatocellular carcinoma, and identification of how to treat infection about various liver diseases. Thus, the combination of AI models in NC-MRI can make accurate staging of liver fibrosis. This advancement can further improve diagnostic and therapeutic decision-making for patients with chronic liver conditions.

U.S. Liver Fibrosis Treatment Market Size and Growth 2025 to 2034

The U.S. liver fibrosis treatment market size was exhibited at USD 4.87 billion in 2024 and is projected to be worth around USD 14.18 billion by 2034, growing at a CAGR of 11.27% from 2025 to 2034.

North America accounted for the largest share of the liver fibrosis treatment market in 2024. With the increasing incidence of liver diseases, including NAFLD and hepatitis, there is a need for efficient diagnostic platforms. With the rise in liver diseases, patients are encouraged to seek professional care, and the number of patients is rising. The increased innovations in diagnostics methods, such as noninvasive imaging and biomarker tests, improve diagnosing and increase the survival of patients. The strong regulatory support and initiatives expected to improve liver disease awareness contribute to market growth. The major pharmaceutical and biotech companies in North America raise a competitive environment, driving research and development of new diagnostic solutions.

• According to the National Institute on Alcohol Abuse and Alcoholism 2023, in 2022, about 29.5 million individuals in the United States with alcohol dependence, or 10.5% of individuals aged between 12 years and above. This was 17.4 million males of 12 years of age and above and 12.2 million females of 12 years of age and above who tested positive for alcohol dependence.

Asia Pacific is anticipated to witness the fastest growth in the liver fibrosis treatment market during the forecasted years. With the rising incidence rates of liver diseases, including hepatitis B & C and non-alcoholic fatty liver disease (NAFLD), the need for efficient diagnostic tests is on the rise. Liver-related diseases prevalent in countries like China, Japan, South Korea, and India have been proven to be on the increase due to rapid urbanization and lifestyle changes. There are several factors affecting liver treatment in the region, like the rising incidence of liver diseases and the deficiency of healthcare workers. Rising incidences are due to lifestyle changes, obesity, and urbanization.

Market Overview

Liver fibrosis leads to the deposition of extracellular matrix (ECM) components, predominantly collagen I and III, and fibrous septum that can impair the overall integrated hepatic performance. The main risk factors for liver fibrosis are alcohol consumption, chronic HCV infection, Non-alcoholic fatty liver disease, and NASH (steatosis not caused by alcohol use). Liver fibrosis is characterized by common molecular mechanisms, including hepatocyte death, chronic inflammation with disruption of the epithelial or endothelial barrier, cytokine release, and activation of HSCs.

The liver fibrosis treatment market is growing due to the rising incidence of injuries and inflammations in the liver that trigger excessive deposition of proteins like collagen and glycoproteins in between the hepatic cells. Besides, the increasing cases of risk factors like excessive consumption of alcoholism, obesity, autoimmune hepatitis, and destruction of bile ducts are further fueling the market growth. The advancements in next-generation plasma protein profiling, which help identify potential biomarkers of liver fibrosis and understand the disease mechanisms that can guide personalized treatment strategies, are also creating a positive outlook.

Liver Fibrosis Treatment Market Growth Factors

• Rising prevalence: The rising number of liver diseases such as Hepatitis, NAFLD, and alcoholic liver disease shows that more patients exist across the world for effective treatment of liver fibrosis, which fuels the liver fibrosis treatment market growth.
• Improved diagnostics: Advanced diagnostic prospects including imaging and biomarkers indicate early detection of liver fibrosis hence allowing for timely treatment hence the market for an efficient product or treatment leads to the growth of the market.
• Increased awareness: Increased knowledge of liver diseases and fibrosis enhances its identification and treatment, leading to market growth.

Market Scope

Market Dynamics

Driver

Increasing prevalence of liver fibrosis

Increased occurrence of various liver disorders, including autoimmune hepatitis, NAFLD, alcoholic liver disease, chronic hepatitis B and C, and liver fibrosis, is on the rise. These illnesses, when advanced, lead to liver fibrosis. Increased incidence of liver fibrosis all over the world is expected to boost the market. The rising incidence of risk factors like chronic Hepatitis B or C, HIV/AIDS co-infection, or taking immune-suppressing drugs post-liver transplantation is expected to boost the liver fibrosis treatment market. Moreover, the growth in the incidence of Liver Fibrosis around the globe has contributed to the market growth. Furthermore, increased spending on healthcare structures, ongoing advancements in the healthcare sector, and various government schemes have been launched to improve the health of people.

• The study conducted by the National Center for Biotechnology Information reveals that in the year 2023, liver disease will become a major problem worldwide, and it will be responsible for a 4% mortality rate around the globe.
• According to the study published in Clinical and Molecular Hepatology in October 2022, the percentage of the global population with NAFLD is expected to rise to 55.7 percent by 2040. As a result, a rise in liver diseases has also heavily contributed to the market.

Restraint

High cost of drug development

The product development of hepatotropic drugs is quite essential; the cost-bearing involved in these therapies is quite expensive, and this hampers the liver fibrosis treatment market growth. Every new pharmaceutical drug to the market undergoes preclinical research, clinical trials, and the approval process by regulatory and marketing of the product, which is time-consuming and costly. For pharmaceutical firms as well as biotech firms interested in investing in liver fibrosis research and development, the high cost of drug development and clinical trials remains a challenge.

Opportunity

Growth in research and development activities

The growth of the liver fibrosis treatment market is supported by rising research and development activity. The former will generate favorable opportunities for the expansion of the market. In addition to this, an increase in drug approval along with product launches. Also, higher investment in newer technologies and an increase in the number of emerging economies all add to the increased chances for the liver fibrosis treatment market growth in the forecast period. Opportunities include the rise of new professions and the rising tendency to invest in the development of new superior technologies.

Treatment Type Insights

The hepatotropic drug segment noted the largest share of the liver fibrosis treatment market in 2024. Hepatotropic drugs contribute to enhancing life quality, decreasing mortality rates in patients with liver fibrosis, and thus stimulating market growth. A hepatotropic drug is a drug that has a beneficial action on the liver, liver cell proliferation, and any process of liver detoxification. This growth is associated with the enhanced awareness of new drugs. Additionally, hepatitis is a sickness that mostly involves the liver and, subsequently, the digestive system and the brain in the worst three stages.

Condition Insights

The hepatitis C segment has contributed the largest share of the liver fibrosis treatment market in 2024. Hepatitis C is a viral disease that is mainly targeted to the liver and, if left untreated, leads to acute as well as chronic liver disease. Other means of transmission are through the exchange of needles/syringes and other sharps or through receiving an unsafe blood transfusion or other unsafe medical procedures using unscreened blood products. There is a growing number of government activities to address the problem, and the enhanced understanding of the need to treat hepatitis C also contributes to the segment's growth. Hepatitis C patient demographics have reduced due to an increased awareness of the disease and also due to the effectiveness of the presently available drugs.

• Worldwide, Hepatitis C affects about 50 million people, with 1 million new cases every year. The WHO noted that in 2022, around 242,000 deaths were related to Hepatitis C, mostly because of cirrhosis and hepatocellular carcinoma.

End-use Insights

The hospitals segment dominated the global liver fibrosis treatment market in 2024. The majority of patients attend hospitals that incorporate diagnostic testing devices into their healthcare facilities. Therefore, the early detection and better diagnosis of diseases, as well as the availability of hospitals to deliver quality care to patients, are the factors currently driving the growth of the market. The increase in the incidence of hepatitis and other liver diseases across the globe has increased the utilization of hospitals for clinical diagnosis and, therefore, fueling the market. In addition, most of the mentioned hospitals possess highly developed imaging departments, including computed tomography (CT), Magnetic resonance imaging (MRI), and ultrasound, which are crucial for the diagnosis of liver diseases. Further, the hospitals offer invasive procedures like liver biopsies to get actual data on the state of the liver.  This is because the majority of the patients depend on hospitals, which are mostly equipped with disease diagnostics. In addition, improvements in the existing framework of the healthcare sector also contributed to expanding the perspective of the segment.

Liver Fibrosis Treatment Market Companies

• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb
• Johnson and Johnson
• Novartis AG
• Vertex Pharmaceuticals Incorporated
• Pfizer Inc.
• FibroGen, Inc.
• Inventiva Pharma
• Pharmaxis Limited

Latest Announcements by Industry Leaders

• In March 2024, Madrigal Pharmaceuticals announced FDA approval of Rezdiffra (resmethrin) for the treatment of patients with noncirrhotic NASH with moderate to advanced liver fibrosis. Commenting on the trial, Bill Sibold, Chief Executive Officer of Madrigal, noted that NASH with moderate to advanced liver fibrosis is a severe and progressively acting disease of the liver. Thus, the acceleration approval of Rezdiffra is the result of more than 15 years of research.

Recent Developments

• In August 2024, Lumos Diagnostics announced that it increased the current deal with Burnet Diagnostics Initiative to create a point-of-care test to support liver functions.
• In March 2024, Gilead Sciences acquired CymaBay, thereby giving Gilead the potential for the best in disease therapy for patients suffering from primary biliary cholangitis. This acquisition allowed the company to conduct advanced research in liver diseases at that time.
• In January 2024, Sanofi acquired Inhibrx, Inc. which extended the portfolio of medicine for the company. This acquisition aims for the company to acquire potential rare disease assets for Alpha-1 Antitrypsin Deficiency (AATD) assets to its portfolio.

Segments Covered in the Report

By Treatment Type

• Peroxisome Proliferator-Activated Receptors (Par)-Alpha Agonist
• Ace Inhibitors
• Hepatotropic Drug
• Others

By Condition

• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis

By End User

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa